PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
Propanc Biopharma, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.32−0.03 (-7.31%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.8%
0M of 6M shares
Institutional holders
4
4 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PPCB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 25,550 | 0.40% | $38.32K | New | 0.00% |
| Citadel Advisors LLC | 12,090 | 0.19% | $18.14K | New | 0.00% |
| Hrt Financial LP | 10,242 | 0.16% | $15 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | 0.00% | $3 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.8% | 4 / 0 | 0 / 0 | 0M | 0M |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James Andrew Nathanielsz CEO/CFO, Director | Aug 17, 2021 | Award | +2,800,000 | – | – | 2,800,000 |
| James Andrew Nathanielsz CEO/CFO, Director | Aug 17, 2021 | Award | +5,928,000 | – | – | 5,928,004 |
| Julian Norman Kenyon Chief Scientific Officer, Director | Aug 17, 2021 | Award | +3,420,000 | – | – | 3,420,005 |
| Julian Norman Kenyon Director | Feb 4, 2015 | Other | +17,654,470 | – | – | 28,466,534 |
| James Andrew Nathanielsz CEO, CFO, Secretary, Treasurer, Director | Feb 4, 2015 | Other | +33,259,350 | – | – | 42,711,111 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Jul 5, 2013 | Sale | −55,000 | $0.09 | $4.95K | 9,701,761 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Jan 23, 2013 | Sale | −15,000 | $0.20 | $3.00K | 9,756,761 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Dec 13, 2012 | Sale | −5,500 | $0.20 | $1.10K | 9,771,761 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Sep 14, 2012 | Sale | −5,000 | $0.20 | $1.00K | 9,777,261 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Sep 4, 2012 | Sale | −250,000 | $0.20 | $50.00K | 9,782,261 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Aug 23, 2012 | Buy | −250,000 | $0.20 | $50.00K | 9,782,261 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.